0 rating

Risk – Recurrence or Contralateral Disease

Mamounas EP, Anderson SJ, Dignam JJ et al.

Aultman Health Foundation, Canton, OH, USA.

 J Clin Oncol 2012;30:3960–6.

Lukas Schwentner’s review: The present study is an analysis of predictors of locoregional recurrence (LRR) in breast cancer patients treated with neoadjuvant chemotherapy. The rationale for the trial was the controversy regarding the optimal use of adjuvant radiotherapy in the subgroup of neoadjuvant therapy-treated breast cancer patients. The authors included patients from the NSABP (National Surgical Adjuvant Breast and Bowel Project) B-18 and B-27 studies, both neoadjuvant trials using cyclophosphamide or cyclophosphamide plus docetaxel in the neoadjuvant chemotherapy setting, and both including patients with operable stage T1–3 breast cancer. In both trials, radiotherapy was mandatory after breast-conserving surgery (BCS), but patients undergoing mastectomy did not receive radiotherapy. Radiotherapy of regional axillary lymph nodes (ALNs) was not feasible in the trials.

Return to top

LATEST ARTICLES

Our most popular articles